Inhalable nanomedicine for lung cancer treatment

被引：0
作者：
Zhang S. [1 ]
Li R. [1 ]
Jiang T. [1 ]
Gao Y. [1 ]
Zhong K. [1 ]
Cheng H. [1 ,3 ]
Chen X. [1 ]
Li S. [1 ,2 ]
机构：
[1] Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou
[2] Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou
[3] Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou
来源：
Smart Materials in Medicine | 2024年 / 5卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Inhalation; Lung cancer; Nanomedicine; Targeted treatment;
D O I：
10.1016/j.smaim.2024.04.001
中图分类号：
学科分类号：
摘要：
Lung cancer has surpassed other types of cancer to become the primary cause of cancer-related deaths. Surgery stands as the foremost clinical treatment strategy available for tackling this condition, but it receives a low efficiency for most patients. In recent years, some adjuvant therapies are employed to improve the lung cancer treatment efficiency, such as chemotherapy, targeted therapy and immunotherapy. However, these strategies have not significantly increased overall survival of patients. Additionally, the random distribution of drugs will induce severe side effects. Nanomedicines have got great attentions to boost drug effect and reduce adverse reactions, including liposome-based nanoparticles, polymeric nanoparticles, inorganic nanoparticles, and exosomes. Importantly, nanomedicines contribute to improving drug bioavailability, stability and residency in target regions. Benefiting from the physiological characteristics of lung, the inhaled pulmonary delivery strategy in combination with nanomedicine will provide a non-invasive and effective strategy for treating lung cancer. Furthermore, the use of targeting ligands enables precise delivery of loaded drugs to lung cancer cells. Inhaled nanomedicine exhibits unique distribution and sustained release behaviors in the alveoli, amplifying the therapeutic effect and reducing side effects. This review aims to discuss various inhaled methods of delivering nanomedicine to treat lung cancer and also summarizes the clearance mechanism of nanomedicine in the lung. Overall, this review focuses on the application of different inhalable nanomedicines, which may inspire the development of more effective treatments against lung cancer. © 2024 The Authors
引用
收藏
页码：261 / 280
页数：19
相关论文
共 154 条
[1]  
Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca - Cancer J. Clin., 70, 4, (2020)
[2]  
Herbst R.S., Morgensztern D., Boshoff C., The biology and management of non-small cell lung cancer, Nature, 553, 7689, pp. 446-454, (2018)
[3]  
Semenova E.A., Nagel R., Berns A., Origins, genetic landscape, and emerging therapies of small cell lung cancer, Genes Dev., 29, 14, pp. 1447-1462, (2015)
[4]  
Mukherjee A., Paul M., Mukherjee S., Recent progress in the theranostics application of nanomedicine in lung cancer, Cancers, 11, 5, (2019)
[5]  
Wang M., Herbst R.S., Boshoff C., Toward personalized treatment approaches for non-small-cell lung cancer, Nat. Med., 27, 8, pp. 1345-1356, (2021)
[6]  
Thai A.A., Solomon B.J., Sequist L.V., Gainor J.F., Heist R.S., Lung cancer, Lancet, 398, pp. 535-554, (2021)
[7]  
Hirsch F.R., Scagliotti G.V., Mulshine J.L., Kwon R., Curran W.J., Wu Y.L., Paz-Ares L., Lung cancer: current therapies and new targeted treatments, Lancet, 389, pp. 299-311, (2017)
[8]  
Kumar M., Jha A., Dr M., Mishra B., Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy, Expet Opin. Drug Deliv., 17, pp. 1459-1472, (2020)
[9]  
Shen A.M., Minko T., Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery, J. Contr. Release, 326, pp. 222-244, (2020)
[10]  
Haque S., Whittaker M.R., McIntosh M.P., Pouton C.W., Kaminskas L.M., Disposition and safety of inhaled biodegradable nanomedicines: opportunities and challenges, Nanomed. Nanotechnol. Biol. Med., 12, 6, pp. 1703-1724, (2016)
12345678910